Metsera, Inc. disclosed that its Board of Directors has determined a revised acquisition proposal from Novo Nordisk A/S to be a "Superior Company Proposal" compared to its existing agreement with Pfizer. Under the terms of its current agreement with Pfizer, Metsera and Pfizer now have a two-day period to negotiate potential adjustments. The Pfizer Merger Agreement remains in effect, and no action is currently required from Metsera shareholders.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metsera Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CG15149) on November 04, 2025, and is solely responsible for the information contained therein.